Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations to PKD1 or PKD2, triggering progressive cystogenesis and typically leading to end-stage renal disease in midlife. The phenotypic spectrum, however, ranges from in utero onset to adequate renal function at old age. Recent patient data suggest that the disease is dosage dependent, where incompletely penetrant alleles influence disease severity. Here, we have developed a knockin mouse model matching a likely disease variant, PKD1 p.R3277C (RC), and have proved that its functionally hypomorphic nature modifies the ADPKD phenotype. While Pkd1 +/null mice are normal, Pkd1 RC/null mice have rapidly progressive disease, and Pkd1 RC/RC animals develop gradual cystogenesis. These models effectively mimic the pathophysiological features of in utero-onset and typical ADPKD, respectively, correlating the level of functional Pkd1 product with disease severity, highlighting the dosage dependence of cystogenesis. Additionally, molecular analyses identified p.R3277C as a temperature-sensitive folding/ trafficking mutant, and length defects in collecting duct primary cilia, the organelle central to PKD pathogenesis, were clearly detected for the first time to our knowledge in PKD1. Altogether, this study highlights the role that in trans variants at the disease locus can play in phenotypic modification of dominant diseases and provides a truly orthologous PKD1 model, optimal for therapeutic testing.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD [MIM no. 173900 for PKD1 and 613095 for PKD2]) is one of the most common monogenic disorders, with a prevalence of 1:400 to 1:1,000 (1, 2) . It is genetically heterogeneous and has been linked to 2 loci, PKD1 (16p13.3) and PKD2 (4q21), mutated in approximately 85% and 15% of cases, respectively (3) (4) (5) . Typically, the disease manifests with progressive bilateral cystic kidney enlargement, leading to end-stage renal disease (ESRD) in midlife; while, symptomatic polycystic liver disease, hypertension, and an enhanced level of intracranial aneurysms are other disease complications (6, 7) .
The pathogenesis underlying the polycystic kidney disease (PKD) phenotypes is still unclear; however, various cellular defects have been suggested. For example, cyst development has been strongly associated with defects to the primary cilia, as evident from model systems and syndromic PKD forms, categorizing PKD as a ciliopathy (8, 9) . Structural and functional cilia defects, including length abnormalities, have been characterized in several types of PKD, including the infantile onset autosomal recessive form (ARPKD, MIM no. 263200) (8) (9) (10) (11) (12) . However, no clear ciliary structural abnormalities have been described in PKD1 (13) (14) (15) . The majority of ciliogenes appear to maintain the structural integrity of the cilia or regulate protein trafficking to and from the organelle, while the PKD1 and PKD2 proteins, polycystin-1 (PC-1) and polycystin-2 (PC-2), respectively, are thought to form a complex on the primary cilium and act as a receptor (14, (16) (17) (18) (19) . One possibility is that the PC complex acts as a mechanosensor, signaling via a Ca 2+ influx through PC-2, a TRP channel, after fluid flow detection by PC-1 (14, 16, 20) . Additionally, urinary exosomelike vesicles (ELVs), which contain high levels of the polycystins, have been suggested to play a role in the mediation of signaling events at the primary cilia (11, 21, 22) . However, the localization and function of PC-1 and PC-2 are still controversial, and various alternative cilia-related roles have been proposed (16, (23) (24) (25) (26) .
In addition to primary cilia defects, PKD cells exhibit many other cellular aberrations proposed to be associated with cystogenesis and/or cyst progression. These defects include, but are not limited to, dedifferentiation, increased proliferation and apoptosis, polarity defects, and altered gene expression that may be linked to increased intracellular cAMP, possibly associated with decreased intracellular Ca 2+ (16, 27) . The tubule segment that becomes cystogenic is also a point of debate in ADPKD. Traditionally, all tubule segments have been thought to be involved in disease, but the available data are limited and somewhat contradictory (28) (29) (30) . Recently, treatments focused on lowering cAMP by targeting the arginine V2 vasopressin receptor (AVPR2), which is mainly expressed in the thick ascending limb of Henle and the collecting duct (CD), highlight the importance of clarifying this issue for the development of successful therapeutic interventions (28, 31, 32) . Unfortunately, the currently available PKD1 rodent models are not ideal for the analysis of ADPKD pathogenesis, including determining the affected nephron segment or therapeutic testing. Pkd1-null animals die embryonically, and heterozygotes develop only very mild disease in old age, while conditional models do not reflect the disease development in human ADPKD due to the loss of all functional protein at one time (33) (34) (35) (36) (37) (38) (39) . In addition, previously described hypomorphic mouse models develop very rapidly progressive disease, which is inadequate for therapeutic testing and does not reflect the gradual kidney enlargement typical of ADPKD (40, 41) .
The severity of disease in ADPKD has been directly associated with the gene mutated; PKD1 on average leads to ESRD at approximately 54 years, while PKD2 leads to ESRD at approximately 74 years (42) . The complete phenotypic spectrum, however, ranges from rare in utero-onset cases to patients with adequate renal function in old age; extreme heterogeneity that cannot be solely explained by genic effects (6, 43, 44) . Some rare cases with early-onset ADPKD also develop tuberous sclerosis due to a contiguous deletion of PKD1 and TSC2 (MIM no. 600273), highlighting TSC2 as a likely modifier of the PKD1 phenotype (45) (46) (47) . Causes of extreme intrafamilial phenotypic variation include mosaicism or bilineal inheritance of a pathogenic PKD1 and PKD2 variant, but these do not account for the majority of cases with extreme ADPKD phenotypes (45, 48, 49) .
The mechanism by which a heterozygous mutation results in cyst development is controversial (50) . Complete loss of the ADPKD proteins in mice results in embryonic lethality and renal cyst development by E14.5 (33, 35, 51) . Likewise, the corresponding human genotype is thought to be incompatible with life (52) . One proposed mechanism, consistent with cyst development in null animals and the focal nature of cystogenesis, is a cellular recessive one, where each cyst is a clonal development resulting from complete polycystin loss. Somatic mutations to the WT PKD1 or PKD2 allele in individual cyst linings support this 2-hit mechanism, while the frequency and timing of this inactivation may explain some of the observed variable expressivity (53) (54) (55) (56) . Consistent with this, a Pkd2 allele prone to somatic recombination results in progressive cystic disease, and PKD severity in conditional ADPKD mice differs radically depending on the age at complete polycystin inactivation (36) (37) (38) 57) .
Although the cellular recessive mechanism is attractive, recent data indicate that the dosage level of the polycystins may be important. Homozygous Pkd1 and Pkd2 hypomorphs, with 13% to 33% correctly spliced Pkd1 or Pkd2, are viable but develop progressive cystic disease in the kidney, liver, and pancreas, despite the presence of some functional polycystin (40, 41, 58) . Additionally, recently described atypical ADPKD families highlight the role of putative incompletely penetrant PKD1 or PKD2 alleles. If inherited alone, these alleles are associated with mild PKD, while homozygotes or compound heterozygotes are viable and present with typical to severe disease, and in trans inheritance with a null allele causes in utero-onset disease (29, (59) (60) (61) (62) . However, proving the importance of specific alleles and analyzing the molecular mechanism is not possible from the study of a number of small families.
Here, we have taken an experimental approach by developing a knockin mouse model of a clinically proposed incompletely penetrant PKD1 allele, p.R3277C (RC), to rigorously test a dose-de-
Figure 1
Generation of the Pkd1 p.R3277C knockin mouse. (A) Diagram of the targeting construct used for injection into ESCs. Restriction sites flanking the construct are in green (Sb, SbfI; Mo, MboI). The Pkd1 p.R3277C mutation was introduced using the exact codon found in ADPKD probands (29, 59 ) (red). Restrictions sites used for introducing the mutation and the loxP-flanked (red triangles) selection cassette (yellow box) are in orange (A, AdhI; X, XhoI; S, SalI). The restriction site used to linearize the targeting construct is shown in purple (P, PacI). RT-PCR analysis across the mutation and the loxP-containing intron of a WT and a homozygous animal (after Cre-lox recombination). A normally seen alternative splice product, skipping exon 31 (in-frame change), was not significantly different between WT and homozygous animals (asterisk) (105) (PCR product, 762 bp; splice variant, 669 bp). (E) Quantification of PC-1 protein levels in whole kidney and CD cell lysate. PC-1 protein levels between WT and Pkd1 RC/RC animals were not significantly different (WB not shown, see Figure 9 for more detail). Data are shown as a normalized ratio (loading control, γ-tubulin [TUBG1]) between WT and Pkd1 RC/RC animals (n = 3/group). Statistical values were obtained by Student's t test; error bars indicate ± SD. pendent pathomechanism of cystogenesis and to investigate the role of these alleles in severe ADPKD. Furthermore, by generating models mimicking the pathophysiological features of typical and in utero-onset ADPKD, we have been able to study the process of cystogenesis in detail at the histological and molecular level, providing insights into pathogenesis and reagents to improve therapeutic options for this disorder.
Results

Generation of a knockin mouse model mimicking a clinical PKD1 allele.
The PKD1 p.R3277C allele was first identified in a consanguineous family of French ancestry in the United States, in which patients homozygous for the allele were viable but presented with mild to typical cystic disease (59) . In 2 additional families with extreme intrafamilial disease variability, this allele segregated in trans with either a truncating or missense mutation, both resulting in very early-onset ADPKD (29, 59) . These associated phenotypes suggested that the p.R3277C allele was incompletely penetrant. To date, 7 pedigrees (2 homozygous) have been identified with this variant, giving an ADPKD population allele frequency of 0.25% (ADPKD database [PKDB] ; http://pkdb.mayo.edu). To rigorously test the role of such alleles in the variable expressivity of PKD1, we generated a knockin mouse model mimicking the exact codon usage seen in patients (Pkd1 c.9805.9807AGA>TGC). The targeting construct was cloned from a 129Sv/E phage library using recombineering ( Figure  1A and ref. 63 ). Embryonic stem cell (ESC) clones were screened for homologous recombination (HR) by Southern blotting, and the mutation was verified by Sanger sequencing (Figure 1 , B and C). To exclude effects of the loxP-flanked puromycin selection cassette, all male germline transmitting chimeras were crossed with an oocyteexpressing Cre female (129S1/Sv-Hprt tm1(cre)Mnn /J) to excise the selection cassette at the zygote stage. Subsequent RT-PCR analysis of the kidneys from homozygous animals (Pkd1 RC/RC animals) showed no alteration in mRNA splicing or expression levels ( Figure 1D ). Likewise, PC-1 expression was unaltered between WT and Pkd1 RC/RC animals when analyzing kidney whole cell lysates or kidney-derived CD cells (in kidney, PC-1 expression in Pkd1 RC/RC was 94% ± 2.30% of WT, P = 0.450; in CD cells, PC-1 expression in Pkd1 RC/RC was 99% ± 2.30% of WT, P = 0.605; Figure 1E ). This suggested that the defect in the action of this allele was likely at the level of functional protein.
Mice homozygous for the Pkd1 p.R3277C allele develop mild but progressive PKD. We first set out to characterize the Pkd1 p.R3277C allele in homozygosity (Figures 2 and 3 , Supplemental Figure  1 , and Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI64313DS1), mimicking the published consanguineous family with adult-onset ADPKD (59) . From a heterozygous cross, we observed the expected Mendelian ratios of offspring (data not shown), implying that Pkd1 Table 1 ). (C) %KW/BW increased progressively with cyst burden until 9 months, after which a significant decrease was observed, likely correlated with increased fibrosis (Table 1) . (D) Similar to that in patients with ADPKD, cAMP levels rose with disease burden (16) . (E) Increased kidney damage due to cystogenesis/fibrosis resulted in a significantly elevated BUN after 9 months. The data in C-E were obtained from the same group of animals at each time point (WT, n = 4; Pkd1 RC/RC , n = 6). Statistical values were obtained by the Student's t test (*P < 0.05, **P < 0.01, ***P < 0.001); error bars indicate ± SD. p.R3277C is not a fully penetrant allele. To analyze disease presentation and progression, we initially followed 4 WT and 6 Pkd1 RC/RC littermates by ultrasonography (US). At 3 months of age, cysts ranging from 0.3 to 2.5 mm in diameter were visible in all Pkd1 RC/RC animals ( Figure 2A ). Kidney volumes (KVs) were estimated from 3D M-mode renderings, and it was determined that Pkd1 RC/RC KVs increased progressively over time in most animals and were significantly increased compared with those of WT littermates at all investigated time points ( Figure 2B and Supplemental Table 1 ); although, there was noticeable variability between these outbred animals ( Figure 2B ; e.g., animal no. 3 vs. no. 6). The increase in KV was directly correlated with the progressive but variable increase in cyst burden seen histologically at 3, 6, 9, and 12 months ( Figure   3A and Supplemental Figure 1) Figure 3A and Supplemental Figure 1) . A similar decrease in %KW/BW associated with increased fibrosis has been observed at earlier ages in other hypomorphic Pkd1 models and in late stages of human ADPKD (40, 41, 64) . This steady increase in fibrosis seems mainly to correlate with cyst growth, although some fibrosis is evident when there is minimal cystogenesis. A number of factors, including epithelial paracrine release of A Quantification was performed on a cross section from 1 kidney per animal. Consecutive cross sections were stained for each marker. The percentage of area of cysts originating from the distal tubule (PNA) or the loop of Henle (THP) was consistently below 1% and was not included in the calculations. B The percentage of cyst area per kidney area was decreased due to a rapid increase in overall kidney weight between P12 and 3 months.
proinflammatory and profibrotic mediators, epithelial production of extracellular matrix proteins, and epithelial-mesenchymal transition, likely promote the fibrosis (65) . Analysis of the onset of cystogenesis showed that the Pkd1 RC/RC animals had histologically visible cysts as early as E16.5 (Supplemental Figure 2 ). This compares with approximately E14.5 in Pkd1 null/null mice and highlights that, although these animals are viable, the time of cyst initiation is not radically different from that in the null state (35, 51) . Renal cystic enlargement was accompanied by an increase in renal cAMP, significant after 6 months, as described in other rodent models and patients with ADPKD ( Figure 2D and refs. 16, 39, 66, 67) . Additionally, increasing kidney damage, presumably due to both the development and expansion of cysts and fibrosis (Table 1) , caused a measurable decline in kidney function, detected by a rise in blood urea nitrogen (BUN) above the physiological range (18.6-32.9 mg/dl) by 9 months ( Figure 2E and refs. [66] [67] [68] . Further, histological analysis showed that at 12 months most Pkd1 RC/RC animals developed multiple ductal plate malformations, seen as microhamartomas ( Figure 3B ). These cystic lesions have been reported previously in Pkd1 +/null animals, are characteristic of human ADPKD, and are the progenitors of the liver cysts found in the majority of patients (34, 69) . Pkd1 RC/+ animals did not develop any renal cysts, have any significant differences in renal function from WT, or develop any liver phenotype by 1 year of age (data not shown).
This analysis of homozygous animals showed that the Pkd1 p.R3277C allele is pathogenic, as all analyzed animals developed PKD, dismissing the notion that it may be one of the many silent, nonsynonymous variants detected in PKD1 (PKDB, http://pkdb. mayo.edu). On the other hand, the viability of the homozygotes showed that the allele is not fully penetrant, proving for the first time to our knowledge the existence of incompletely penetrant PKD1 alleles and highlighting their role as a disease modifier.
The Pkd1 p.R3277C allele modifies the Pkd1 +/null phenotype to early-onset disease. To directly test the proposed modifier role of Pkd1 p.R3277C and to mimic the genotype associated with human in utero-onset disease, we crossed Pkd1 RC/+ animals with a well-estab- Table 2 , and refs. 51, 59). Again, we observed the expected Mendelian ratios of offspring (data not shown), but in this case the progression of disease was much more aggressive. Pkd1 RC/del2 animals showed enlarged kidneys by P1, visible from gross anatomy, and a significantly greater %KW/BW compared with that of WT littermates (3.05% vs. 1.29%; Figure 4 , A and C, and Supplemental Table 2 ). The %KW/BW increased rapidly from approximately 3% at P1 to approximately 25% at P25. In comparison, the %KW/BW at P1 of Pkd1 RC/del2 animals was significantly higher than that of homozygous animals at 3 months (P = 0.01). At the histological level, cysts were visible as early as E15.5, and both the number and size of cysts increased in an exponential fashion to at least P25 ( Figure 5 , Figure 6B , Table 1 , and Supplemental Figures 2 and 3) . Interestingly, multiple glomerular cysts were detectable at the early time points, highlighting a clear similarity with human in utero-onset ADPKD ( Figure 5 , insets, and refs. 59, 70) . The rapidly expansive PKD was also associated with premature death, first noted at P20, and with a median survival at P28; 80% of animals were dead by P50 ( Figure 4B ). The cause of death was
Figure 4
Pkd1 RC/null mice develop in utero/early-onset ADPKD. (A) Gross images of WT and Pkd1 RC/del2 kidneys from P1 to P180, illustrating early-onset/ rapidly progressive disease. After P25, the kidney size decreased, likely due to increased fibrosis ( Figure 5 and Table 1 Table 2 ). (C) %KW/BW was significantly increased as early as P1 (3%) and rapidly climbed to 25% by P25. (D) BUN levels rose beyond the physiological average as early as P18. (E) cAMP levels were significantly above normal by P1. Values in C-E were obtained from n ≥ 5 at each time point for both WT and Pkd1 RC/del2 mice. P180 data can be found in Supplemental Table 2 . Statistical values were obtained by the Student's t test (*P < 0.05, **P < 0.01, ***P < 0.001); error bars indicate ± SD.
likely associated with renal failure, as indicated by marked renal cystic enlargement (70.2% of kidney area by P25; Table 1 ), increased fibrotic index (24.2% by P25; Figure 5 and Table 1 ), and uremia evident by a significant increase in BUN at P12 ( Figure 4D and Supplemental Table 2 ). Animals surviving beyond P25 exhibited further evidence of disease progression with significantly elevated BUN levels (~178 mg/dl [P25] vs. ~314 mg/dl [P180], P = 0.006; Supplemental Table 2 ) and a decline in %KW/BW, which is likely associated with an increase in fibrotic tissue (~25% [P25] vs. ~9% [P180]; Figure 4A , Figure 5 , and Supplemental Table 2 ), as with the Pkd1 RC/RC mice at 12 months. The reason that approximately 20% of animals survived much longer is unclear, but it is of note that this outbred population had milder disease during the explosive cyst expansion period (P12-P25), suggesting a less critical role for PC-1 during adulthood. Consistent with a dosage-dependent disease mechanism, Pkd1 RC/del2 animals had a much more rapid rise in cAMP, with P1 mice having higher cAMP levels than 12-month-old Pkd1 RC/RC mice (P = 0.0042) and BUN levels above the physiological average as early as P18 (Figure 2; Figure 4 , D and E; Supplemental Tables 1 and 2; and ref. 68 ). In addition, Pkd1 RC/del2 animals presented with osteopenia and left ventricular hypertrophy (LVH), known extrarenal phenotypes observed in other Pkd1 models and patients with ADPKD (Supplemental Figure 4 and refs. [71] [72] [73] . A decrease in trabecular and cortical bone mass was observed in Pkd1 RC/del2 males and females at P25, likely correlating with reduced PC-1 function in osteoblasts, but possibly also associated with secondary hyperparathyroidism (Supplemental Figure 4A , data on females not shown, and refs. 71, 72) . Heart weight was also significantly increased, with the myocardium of the left ventricle significantly thickened (Supplemental Figure 4B) and evidence of LVH, possibly due to hypertension in the P25 Pkd1 RC/del2 animals with advanced cystic disease. No intracranial aneurysms were noted. This compound heterozygous model clearly demonstrates the role of Pkd1 p.R3277C as a modifying allele. The Pkd1 +/del2 mice did not exhibit an ADPKD phenotype, lacking renal cysts and functional changes in kidneys at 1 year of age (data not shown), contrasting dramatically with the rapid disease progression in Pkd1 RC/del2 animals (51) . These data prove that in trans inheritance of a null and this incompletely penetrant allele, without the requirement of other genetic events, results in early-onset ADPKD, suggesting a clear dosage pathomechanism of cyst initiation and/or progression.
Pkd1 p.R3277C mice show a switch in tubular cyst origin correspondent with age and an increase in proliferation. The models described here developed cysts due to a consistent reduction of PC-1, compared with conditional knockouts, in which only the segments engineered to be null for PC-1 became cystic. Consequently, answering the question of where and when cysts develop in our model is relevant to human PKD1. RC/del2 animals at P1, 82% of cysts were of PT and 17% of cysts were of CD origin. However, by P25, these animals had only 6% PT and 76% CD cysts. Interestingly, by this time point, 18% of cysts (16% of kidney area) could not be recognized by any of the tubule markers used, including PNA and THP ( Figure 6 , A and B, and Table  1 ), suggesting that they had become dedifferentiated. The switch in cyst origin was also noticeable when looking at cyst area rather than cyst number, with the area occupied by PT cysts falling from 29.2% at P1 to 2.9% at P25. During the same period, CD cysts rose from 4.2% of kidney area to 51.3% (Table 1 ). In Pkd1 RC/RC mice, a similar switch was observed; at P1, 90% of cysts were of PT and 8%
Figure 5
Histology of Pkd1 RC/del2 mice highlights early-onset and rapidly progressive cystic disease. Representative Masson Trichrome sections of Pkd1 RC/del2 and WT kidneys from E14.5 to P180. Kidney cysts were clearly visible as early as E16.5 (a few cysts were present at E15.5; Supplemental Figure 2 ) and rapidly increased in number/size with age (Table 1) . Glomerular cysts were present as early as E16.5 (insets) (59) . The kidneys of animals with longer survival (P180) were highly fibrotic, with little obvious healthy tissue. Scale bars: 100 μm (E14.5 to P1); 500 μm (P12); 750 μm (P25 and P180); 50 μm (insets).
were of CD origin, while at 3 months, 76% were of CD and 15% were of PT origin ( Figure 6 , A and C, and Table 1) . Interestingly, at 12 months of age, the percentage of PT cysts increased as compared with that at 3 months, from 15% to 29%; however, most of the PT cysts corresponded to mildly dilated tubules, whereas the majority of larger cysts were either of CD origin (56%, 13.6% of area) or dedifferentiated (15%, 8.5% of area; Figure 6 , A and C, and Table 1 ). The PT dilatation at this stage may reflect acquired renal cystic disease associated with advanced renal insufficiency as seen in human ADPKD (74, 75) .
This analysis of both models shows a consistent shift in cyst origin, with a predominance of PT kidney cysts during kidney development, which continues in the mouse until approximately 2 weeks postnatally, to a predominance of CD cysts once the kidney has fully developed (37) . This is consistent with PT cysts predominating in early-onset ADPKD cases, with a similar shift from PT to CD cysts associated with completion of kidney development in ARPKD (28, 29, 39, 76, 77) . The observation that the majority of adult cysts are of CD origin correlates with the AVPR2 antagonists showing some benefit in ADPKD (31, 32, 78) .
PCNA staining of CD tubules and cysts in P18 Pkd1 RC/del2 animals highlighted that cyst expansion/size correlates with an increase in proliferation ( Figure 7 and Supplemental Table 3 ). Proliferation was greatest in the largest cysts (5.50% vs. 3.09% in small cysts, P = 0.002), but, notably, even nondilated tubules showed increased proliferation compared with WT (1.71% vs.
Figure 6
Pkd1 p.R3277C mice show a switch in tubular cyst origin corresponding to age. (A) IF lectin labeling of PT (LTA) and CD (DBA). During early kidney development (P1), cysts originated mainly from PT in Pkd1 RC/del2 and Pkd1 RC/RC animals, with only rare CD cysts (arrowheads). Later in development (P12), a switch to more CD cysts occurred that became more prominent after kidney development (P25, Pkd1 RC/del2 ; 3 months, Pkd1 RC/RC ), with only a few remaining PT cysts (arrows). With disease progression, an increasing number of cysts seemed to dedifferentiate. Asterisks indicate a lack of labeling with tubule markers. Scale bars: 100 μm (P1); 200 μm (P12); 300 μm (P25); 500 μm (3 months and 12 months). (B) Quantification of cyst origin at P1, P12, and P25 for Pkd1 RC/del2 animals and (C) P1, P12, 3 months, and 12 months for Pkd1 RC/RC animals (n = 3; Table 1 ). Significance is based on cyst number. Statistical values were obtained by the Student's t test (*P < 0.05, **P < 0.01). Data are not shown for distal tubule (PNA) and loop of Henle (THP), as they accounted for <1% of the total cyst number.
0.94%, P = 0.009). The role of proliferation to cyst expansion in ADPKD is a controversial one, but when analysis is limited to tubular/cystic epithelia, increased cell division clearly occurs (36, 37, 79) .
The Pkd1 p.R3277C allele is associated with elongated CD primary cilia. In syndromic forms of PKD, the mutated proteins are proposed to regulate ciliary protein trafficking and, hence, influence ciliogenesis; therefore, structural ciliary abnormalities, including length defects, have been associated with these diseases (8) (9) (10) . However, in PKD1, the majority of studies have not detected cilia length defects, but the data are not conclusive, as these studies were largely conducted by light microscopy using cultured cells (14, 15, 80, 81) . To analyze whether PC-1 may have a role in ciliary maintenance, we analyzed renal CD and bile duct cilia length using scanning electron microscopy (SEM). Cilia of nondilated and cystic CDs were significantly longer in P25 Pkd1 RC/del2 animals (mean = 4.98 μm) and 12-month-old Pkd1 RC/RC animals (mean = 3.02 μm) compared with those in WT controls (mean = 1.98 μm; Figure 8A and Supplemental Table 4 [WT vs. Pkd1 RC/del2 , P = 0.0012; WT vs. Pkd1 RC/RC , P = 5.65 × 10 -4 ]), with a significant difference between Pkd1 RC/del2 mice and their homozygous counterparts (P = 0.0066). Interestingly, these length defects were not related to cystic dilatation, since measurements in cystic and noncystic CDs in both animal models did not significantly differ (Supplemental Table 4 ). Furthermore, this observation was independent of age, since the length of WT cilia did not change from P25 to 12 months of age (Supplemental Table 4 ). Cilia within normal bile ducts did not vary significantly between genotypes ( Figure 8B , Supplemental Table 5 , and ref. 79 ). However, bile duct cilia were elongated in 1 microhamartoma that was found by SEM (P = 1.49 × 10 -6 ; Figure  8B and Supplemental Table 5 ). Therefore, within the kidney, the dosage dependence of cilia length abnormality indicates that the level of functional PC-1 is directly associated with the observed ciliary defect, whereas in the liver, cilia elongations seem related to bile duct abnormalities. Figure 9A and refs. 82, 83). After cleavage, the N-terminal product (NTP) and the C-terminal product (CTP) are thought to remain tethered and functionally act together ( Figure 9A and ref. 83 ). It has also been reported that endogenous PC-1 is observed as 2 distinct glycoforms, endoglycosidase H-resistant (EndoH-resistant) (NTP**) and -sensitive (NTP*) forms (84) . This implies a difference in protein trafficking of these glycoforms, as EndoH resistance is obtained in the transGolgi, in which high-mannose oligosaccharides are converted to complex saccharides by the addition of N-acetylglucosamine to form secreted or membrane-bound, mature, forms of the protein (85) . We confirmed these findings by Western blot (WB) analysis of kidney membrane protein with 2 products found in the untreated sample, one being the EndoH stable form (no shift in size [NTP**]), and the other being the sensitive form that reduces in size upon EndoH treatment (loss of all N-linked glycosylation [NTP*]; Figure 9B) . Treatment with peptide-N-Glycosidase F (PNGaseF), an enzyme that removes all N-linked sugars independent of maturation status, reduced the size of the 2 products to that of the EndoHsensitive form, showing that the difference in size of the 2 untreated products is only due to variable glycosylation status. Analysis of urinary ELVs, showed that it is the EndoH-resistant PC-1 that is present in these vesicles ( Figure 9B and refs. 21, 22) . Comparison of ELV PC-1 with an exogenously expressed PC-1 GPS cleavage mutant (E2771K; Figure 9A ) showed that the PNGaseF-treated full-length PC-1 was much larger than the treated ELV product, indicating that only the cleaved product is found in ELVs (NTP**; Figure 9C ). Also, only the cleaved product (NTP) was observed in kidney tissue preparations, consistent with the significance of this cleavage event for normal function (83) .
The Pkd1 p.R3277C allele alters PC-1 cleavage and folding/maturation.
PC-1 is a multidomain glycoprotein that is cleaved at a G proteincoupled receptor proteolytic site (GPS;
To analyze the possible pathomechanism of Pkd1 p.R3277C, we first investigated whether the allele altered PC-1 cleavage by using an exogenously expressed C-terminally tagged PC-1 construct Table 3 ) (n = 3/group). Statistical values were obtained by the Student's t test (*P < 0.05, **P < 0.01, ***P < 0.001); error bars indicate ± SD.
( Figure 9A ). WB using an antibody to the C-terminal V5 epitope tag highlighted significantly reduced levels of cleaved p.R3277C PC-1 compared with WT (~76% of WT, Figure 9D) . However, we also tested a second suspected incompletely penetrant Pkd1 allele (p.R2220W) that was found in trans with PKD1 p.R3277C resulting in early-onset ADPKD, and this PC-1 product was far more resistant to cleavage (~26% of WT) (29) . The p.R2220W variant is localized within the receptor for egg jelly domain (REJ), a domain previously shown to be important for GPS cleavage (83) . These results suggested that inefficient cleavage may be a pathomechanism associated with some incompletely penetrant PC-1 alleles but may not be central to the reduced function of Pkd1 p.R3277C; hence, we investigated further possible mechanisms. Since PKD1 p.R3277C is 2 amino acids from the second transmembrane domain (TMII; Figure 9A ), we tested whether TMII integrates appropriately into the lipid bilayer in the presence of this missense change. Using exogenous expression of a partial PC-1 construct with a C-terminal glycosylation reporter, we assayed successful TMII integration. However, no noticeable difference in membrane integration ability was found compared with WT (Supplemental Figure 5) .
Since the cleaved, mature PC-1 is found in urinary ELVs, it was possible to use urinary ELVs from WT and mutant mice to assay possible folding or trafficking defects. We isolated ELVs from a 12-hour urine collection of 1-and 12-month-old Pkd1 RC/RC mice and found from WB analysis that they had an approxi-
Figure 8
Primary cilia are elongated in Pkd1 p.R3277C CDs but not normal bile ducts. SEM analysis of primary cilia length (A) in the CDs (Supplemental Table  4 ) and (B) bile ducts (Supplemental Table 5 ) of WT, Pkd1 RC/del2 , and Pkd1 RC/RC mice at the ages indicated (n = 3 animals/group). (A) Representative SEM images of CDs and individual cilia. Scale bars: 2 μm (bottom row); 10 μm (WT, top row); 15 μm (Pkd1 RC/del2 and Pkd1 RC/RC , top row) (left). Graph summarizing >100 cilia measurements (~40 cilia in nondilated, ~30 in dilated, and ~30 in cystic CDs) in mutant animals and >50 cilia of nondilated CDs in WT animals (P25 and 12 months). The level of functional Pkd1 inversely correlated with cilia length, indicating a role of PC-1 in cilia maintenance (right). (B) Representative SEM image of WT and Pkd1 RC/RC bile duct and one microhamartoma. Bile duct cilia of the microhamartoma were significantly elongated (6.24 ± 1.57 μm, P < 0.001) (left). Scale bars: 1 μm (WT and Pkd1 RC/RC , bottom row); 2 μm (microhamartoma, bottom row); 50 μm (Pkd1 RC/RC , top row); 100 μm (WT and microhamartoma, top row). Graph summarizing >50 cilia measurements of >5 bile ducts per animal (right). Statistical values were obtained by the Student's t test (**P < 0.01, ***P < 0.001); error bars indicate ± SD. mately 61% reduction of the mature, EndoH-resistant PC-1 glycoform compared with WT; all mutant PC-1 found in ELVs was EndoH stable, highlighting that the mutant protein trafficked appropriately ( Figure 9, E and F) . Analysis of ELVs collected from Pkd2 WS25/-mice that have a similar level of cystogenesis as the analyzed Pkd1 RC/RC mice showed unaltered levels of PC-1 NTP** compared with WT mice, highlighting that the reduction in PC-1 in the Pkd1 RC/RC mice is not due to the presence of cystic disease (57). To confirm these findings in the kidney, we performed WB of kidney membrane preparations of 1-month-old littermates. Consistent with the results from the urinary ELVs, Pkd1 RC/RC animal kidneys showed a reduced level of the EndoH stable PC-1 NTP** compared with WT ( Figure 9G ).
These results suggested that the reduction of EndoH stable PC-1 p.R3277C may result from a maturation defect between the ER and the trans-Golgi or from a folding defect within the ER (85) . To investigate a possible folding defect, primary cells isolated from Pkd1 RC/RC kidney CDs were grown at a reduced temperature to create an environment more permissive for protein folding (33°C, compared with 37°C) (86) . Indeed, the temperature shift increased the relative amount of the EndoH stable PC-1 glycoform in cellular ELVs to a level close to that in WT ELVs and significantly different from that at the higher temperature ( Figure 9H, Figure 6 ). Therefore, due to the folding defect (and reduced cleavage), p.R3277C results in an approximately 60% reduction of mature PC-1 in Pkd1 RC/RC mice.
Discussion
In this study, we set out to understand the etiology and pathomechanism associated with the phenotypic heterogeneity of PKD1, which at its extremes ranges from mild PKD in old age without renal insufficiency to in utero lethality (6, 43, 44) . Emerging family data suggested that in trans inheritance of a null and an incompletely penetrant PKD1 allele could result in the devastating early-onset phenotype (29, (59) (60) (61) . To rigorously test this theory, we developed and characterized a knockin mouse model mimicking a naturally occurring PKD1 variant, p.R3277C, highlighted by recent family studies (29, 59) . Mirroring the human studies, Pkd1 RC/RC animals developed gradual cystic disease over 1 year, while Pkd1 RC/null mice had rapidly progressive disease, proving the significance of this combination of alleles. This simple pathomechanism is consistent with the description by Zerres (43) , nearly 20 years ago, of a high recurrence risk of severe disease in siblings of an early-onset case in families with otherwise typical ADPKD. Data from a handful of additional families, highlighting other possible incompletely penetrant alleles, indicate a broader applicability, but studies of larger populations and better definition of these alleles are needed to determine the full importance of in trans inheritance to explaining early-onset disease (29, (59) (60) (61) (62) . Indeed, other mechanisms, such as modifier loci beyond the disease gene and environmental factors, also significantly influence disease variability. Early-onset severe ADPKD has been linked to contiguous deletion of PKD1 and TSC2 as well as co-inheritance of a PKD1 and a HNF1B or PKHD1 allele, highlighting the fact that digenic inheritance may account for some of the phenotypic variability seen in ADPKD (45) (46) (47) 62) . Further, 3 SNPs in DKK3 have been associated with severity of renal disease in a candidate gene association study, while nongenetic factors, such as male hormones, caffeine, and smoking, have been suggested as risk factors in ADPKD (87) (88) (89) . Careful analysis is now required to determine the significance of each of these elements with respect to disease severity and to identify other genetic and environmental disease modifiers. Insights from our model systems into the etiology of in utero ADPKD and the functional analysis of the mutant PC-1 provide further clues to the underlying pathomechanism of typical ADPKD. Although cystogenesis is often considered a cellular recessive process, in our case both the Pkd1 RC/RC and Pkd1 RC/del2 animals have a Pkd1 mutation to both alleles, making it unlikely that a somatic Pkd1 mutation is required for cyst initiation. Instead, it seems more plausible that the dosage of PC-1 is underlying disease severity, and, by expression analysis of PC-1 in ELVs (an abundant site of polycystin expression that is readily isolated), we have precisely quantified the levels of mature protein associated with progressive adult disease (~40% in Pkd1 RC/RC ) and inferred a level of mature protein associated with rapidly progressive, early-onset disease (approximately 20% in Pkd1 RC/del2 and ref. 21 ). Hence, it seems reasonable to propose that ADPKD severity is directly related to PC-1 dosage; adult-onset disease is usually caused by a 50% PC-1 reduction (haploinsufficiency), while further reductions due to variants on the "normal" allele cause severe early-onset presentations. The progressive PKD associated with transgenic miRNA reduction of Pkd1 by 60% to 70% is consistent with the dosage model presented here (90) . Although, there is strong evidence of a second-hit mechanism, with detected somatic mutations in large cysts, we propose that they are not necessary for cyst initiation and instead may play a role in cyst progression by providing cysts a growth or survival advantage (53) (54) (55) (56) .
The combination of a dosage pathomechanism in ADPKD and the realization that variants of the disease gene inherited from the "normal" parent can significantly influence the PKD1 phenotype have profound implications for understanding the variable expressivity of ADPKD. We have focused on extreme early-onset disease through co-inheritance of an incompletely penetrant and fully penetrant allele, but some alleles may have a lesser effect on the level of functional PC-1 and result in less extreme effects, such as ESRD in early adulthood. While efforts to identify genetic modifiers of the PKD1 phenotype through genome-wide association studies and exome or whole-genome sequencing are underway, it seems plausible that variants to the "normal" PKD1 allele are a major disease modifier and that complex allelic inheritance is relevant more generally to the variable expressivity of ADPKD. Hence, better classification of variants with incompletely penetrant potential will be of increasing prognostic value. Further, it seems likely that this pathomechanism is important to the phenotypic variability of other haploinsufficient, dominant diseases, although the large array of "normal" variants cataloged at PKD1 indicate that it may be an extreme example (PKDB, http://pkdb.mayo.edu) (91, 92) .
Our models not only allow the genetic mechanism of disease to be analyzed but also provide insight into the pathophysiology. We have shown that increased proliferation is an important factor in cyst expansion. Of further interest, in both models cyst initiation occurred embryonically (E15.5-E16.5), but PKD developed much more quickly in the model with the lower level of PC-1. It is not known whether this dosage difference influences the rate of cyst initiation or expansion, but in this study, it seems that dosage may be relevant in both instances. Previous comparisons of PKD1 and PKD2 concluded that it was the rate of cyst initiation rather than rate of expansion that makes PKD1 more severe (88) . Interestingly, analysis of conditional Pkd1 models showed that PKD severity altered radically depending upon the time of gene inactivation, with a tipping point between rapid and tory, and since conditional models lose all functional PC-1 at one time, with the affected kidney segment dictated by the Cre promoter, they do not reflect human disease development. Previously described hypomorphic models have approximately 70% to 80% PC-1 reduction, leading to very rapid disease with high levels of fibrosis early in life, similar to our approximately 80%-reduction model (Pkd1 RC/del2 ), and thus leaving a short therapeutic window (40, 41) . Our 60%-reduction model (Pkd1 RC/RC ) appears to best mimic human ADPKD (over a shorter timescale) with a 9-month progressive expansion and then a slight reduction in KV associated with fibrosis as ESRD approaches (101) . Other similarities include those observed physiologically, with increased cAMP and elevation of BUN indicating renal insufficiency after 9 months, and histologically, with progressive cyst development and expansion, and a switch from PT to CD cysts following renal development. The temperature-sensitive nature of p.R3277C suggests that interventions to promote more efficient folding of PC-1 may increase the level of functional protein. This indicates that, in addition to the current experimental therapies that focus on cAMP and other signaling defects, chaperone-enhancing or proteasome-inhibiting strategies may also be effective in a subset of patients with missense mutations to PKD1 or PKD2 (102, 103) . Last, a dosage model of ADPKD suggests that approaches to increase the level of the normal PKD1 (PKD2) allele in patients with typical ADPKD, even by a modest amount, could have a dramatic clinical benefit.
Methods
Generation of the knockin construct. The targeting template for the Pkd1 p.R3277C (murine Pkd1 p.R3269C) knockin construct was obtained from a 129/Sv genomic phage library, using a cDNA probe spanning exons 19-23. The identified phage (11.1 kb, Pkd1 IVS16-IVS34) was cloned into pZErO -2TM . oligo.PGK-TK (pZErO -2TM plus oligo [PacI, SbfI, MfeI] plus thymidine kinase gene). A β-lactamase expression cassette flanked with a 3′ SalI site was recombineered into IVS30, using the DY380 E. coli strain (63) . The intronic position of the cassette was assessed (ASD Intron Analysis and ESEfinder 3.0) to minimize the possibility of disrupting spliceosome binding sites or the branch point. The mutation and the loxP-flanked puromycin cassette were introduced using a pZErO -2TM shuttle vector system (AhdI, XhoI, SalI polylinker). An amplified 129/Sv Pkd1 fragment, spanning from the AhdI site (IVS27) to the end of the β-lactamase cassette (XhoI; IVS30), was cloned into the shuttle vector, and Pkd1 p.R3277C was introduced using the Phusion Site-Directed Mutagenesis Kit (NEB) (29, 59) . The loxP-flanked puromycin cassette, including Southern blotting restrictions sites, was excised from pBS.DAT-LoxStop and cloned into the shuttle vector using XhoI/SalI sites. The modified genomic sequence, including the loxP-flanked selection cassette, was excised from the shuttle vector (AhdI/SalI) and exchanged with the original sequence within the targeting construct (pZErO -2TM .PGK-TK) to generate the complete construct. The construct was linearized with PacI ( Figure 1A) .
Generation and genotyping of knockin mice. The targeting construct was electroporated into 129/Sv ESCs by the Mayo Gene Targeting Core as previously described (104) . Successful HR was confirmed by Southern blotting using a 5′ (2.9 kb; exon 15) and 3′ probe (2.0 kb; exons 36-46; Figure 1A ) and 1.5 μg of ESC DNA digested with either BspHI (5′ probe) or MfeI (3′ probe) ( Figure 1A ). ESC clones positive for HR were verified by sequencing and injected into blastocysts of pseudopregnant C57BL/6 females. Germline transmission was obtained with 2 clones. All experiments were performed on generation F3 animals (C57BL/6) from 1 clone (generation F2 was first crossed against the Cre-recombinase expressing line, 129S1/Sv-Hprt tm1(cre)Mnn /J, to remove the selection cassette). Pkd1 +/del2 was a fully congenic C57BL/6 line (51). slow expansion of disease roughly corresponding to the completion of kidney development (37) . Hence, developing tubules with high proliferative indices may be more sensitive to PC-1 reduction/loss. The rate of epithelial cell proliferation during development may also explain the switch with completion of kidney development from predominately PT to CD cysts observed in our study and previously reported in human ADPKD (28) (29) (30) . The proliferation of immature early tubules (S-shaped bodies) is very high and remains high throughout embryonic life (93) . In later development, when the epithelium differentiates into nephron segments recognizable by light microscopy, the proliferative index decreases substantially but remains elevated in the distal nephron and CD, whereas it becomes very low in the PT (93) . In pediatric and adult kidneys, proliferative indices are very low in all tubular segments but remain higher in the CD compared with those in PT (94) . Thus, the underlying rate of epithelial cell proliferation may explain both the increased susceptibility of the developing kidney to cystogenesis and the switch from predominantly PT to predominantly CD cysts. Understanding this switch is important, since theoretical considerations have highlighted that embryonic cysts, by growing at faster rates compared with cysts initiated later in life, contribute majorly to the total cyst burden (95) .
A major argument for the 2-hit hypothesis is that the cyst development in ADPKD is focal, each the result of an individual somatic mutation (50) . However, in the models presented here in which somatic mutations to the normal allele are not likely to be important, cyst development is still focal. This implies that a threshold model is important where stochastic factors, such as variation in the PC-1 expression level from cell to cell and so-called third hits (perhaps to be considered second hits now), such as renal damage or other factors triggering proliferation, may be key to driving a cell or segment of tubule into cystic transformation (96) (97) (98) .
The role primary cilia play in ADPKD cystogenesis remains controversial, with the majority of studies focused on downstream signaling defects (16) . Little attention has been given to the structural appearance of ADPKD primary cilia, despite length and other structural defects detected in other PKD-related ciliopathies (8) (9) (10) (11) (12) (13) (14) (15) . Here, we report for the first time to our knowledge a clear PC-1 dosage-dependent increase in cilia length in normal and cystic CDs. Increased cilia length has been associated with enhanced cAMP levels and injury/inflammation, the latter of which may be associated with the observed increase in cilia length within the microhamartoma; however, within the kidney, it is of interest that we observed the length increase independent of the cystogenic state of the tubule (80, 99, 100) . This highlights a potential direct role of PC-1 in cilia maintenance. Alternatively, the length increase could be a compensatory response to reduced functional PC-1, extending the platform hosting the flow or ELV detector when less PC-1 is present. Furthermore, the clear description of the processing of PC-1 into mature and immature EndoH forms presented here should stimulate further study of the localization of this large and complex protein. Here, we have shown that just the resistant form can be found in urinary ELVs; however, the glycoform found on primary cilia or the plasma membrane remains unknown (21) .
One of the most valuable features of this study is likely the development of new Pkd1 models, which are well suited for therapeutic testing in comparison with current models. As described in the Introduction, the present fully inactivating models are unsatisfac-Biotechnology Inc. ) labeling was performed as indicated (11, 79) , with secondary antibodies (Alexa Fluor, Invitrogen) used at a 1:500 dilution. Cyst number and area were estimated using ImageJ software. A dilated tubule was counted as a cyst, if its area exceeded 0.02% of the total kidney area (~500 μm 2 , dependent on age). For cyst number, cysts were counted using the Analyze Particle/Cell Counter plug-in for ImageJ ( Figure 6 , B and C). For percentage of cyst area, the kidney area (medulla plus cortex) was measured, followed by measurement of the cyst area of individually stained or unstained cysts. Fibrotic area was measured using the Masson Trichrome section. All area calculations were preformed using the Analyze Particle (IF images) or the Measure and Label (Masson Trichrome) plug-in for ImageJ. Results were expressed as percentage of stained area per kidney area (Table 1) . For PCNA analysis, the Axio Vision software was used (Figure 7 ). Single kidney cross sections from 3 nonlittermate mice were labeled and analyzed (consecutive sections from the same kidney were used for each marker).
SEM. SEM imaging was performed on the left kidney and the right liver lobe as described previously (11, 79) . CDs were identified based on known morphological features, and bile ducts were identified based on their proximity to a portal vein/hepatic artery (107) . For kidney SEM, approximately 50 cilia were imaged from each WT animal (two P25 animals and one 12-month-old animal), and cilia of cystic (~30; n > 6), dilated (~30; n > 6), and nondilated (~40; n > 10) CDs were imaged from each mutant animal (three P25 Pkd1 RC/del2 animals and three 12-monthold Pkd1 RC/RC animals). For liver SEM, approximately 50 cilia from at least 5 different bile ducts per animal were imaged from each genotype. In both cases, kidney and liver, genotype-blinded cilia length measurements were made with ImageJ software.
ELV isolation and whole kidney membrane/cell lysate preparation. Urinary ELVs were isolated as described previously (104) . Three male and three female WT or Pkd1 RC/RC animals were placed in metabolic cages for 12 hours to collect 10 ml urine (overall experimental, n = 4). Isolation of urinary ELVs from the Pkd2 WS25/null model as controls was possible because Stefan Somlo (Yale School of Medicine, New Haven, Connecticut, USA) provided us with the model. Cellular ELVs were similarly isolated from primary CD cells grown in 20 ml (six 15-cm plates = 120 ml total) serum-free media for 3 days. Whole kidney membrane preps from 1-month-old WT or Pkd1 RC/RC animals were prepared as described previously (Figure 9, B and G, ref. 104 ). Whole kidney lysates were prepared from 1-month-old WT or Pkd1 RC/RC flash-frozen kidneys (n = 3) after homogenization with mortar and pestle followed by 18G, 21G, and 25G needle homogenization. The homogenate as well as CD cells (n = 3/group; Figure 1D and Supplemental Figure 4B ) were lysed using RIPA buffer (Millipore).
Cleavage and membrane integration assay. The cleavage assay (n = 6) was performed using a full-length Pkd1 construct with a C-terminal V5 tag ( Figure  9D ). To introduce mutations, the fragment was shuttled into pZErO -2TM (EcoRI/SacII). The membrane integration assay (n = 3) was modified from a previously described protocol using a PC-1 transmembrane glycosylation construct provided by Robin Maser (Clinical Laboratory Sciences, University of Kansas Medical Center, Kansas City, Kansas, USA; Supplemental Figure 5 and ref. 108) . In both experiments, the Pkd1 variant was introduced using the Phusion Site-Directed Mutagenesis Kit (NEB), and the WT and mutant constructs were transfected into HEK293T cells following manufacturer protocol (Polyfect, Qiagen). Cells were lysed 24 hours after transfection using RIPA buffer (Millipore).
Primary cell culture/temperature shift assay. Primary CD cells were harvested from 1-month-old WT and Pkd1 RC/RC kidneys (2 animals per harvest, nonlittermates) as described previously (104), with the following modifications: after sieving the cells through 80-μm mesh, the flow through was Genotyping of all Pkd1 p.R3277C animals was performed by HinfI digest of a 719-bp PCR fragment spanning IVS27-exon 30. The p.R3277C mutation destroys the HinfI site (WT, 439 bp, 280 bp; Pkd1 p.R3277C, 719 bp). Pkd1 +/del2 mice were provided by Shigeo Horie (Department of Urology, Teikyo University Hospital, Kanto/Tokyo, Japan) and genotyped using two separate PCR reactions, mutant (474 bp) and WT (380 bp).
RT-PCR analysis. RT-PCR analysis (n = 3) was performed on RNA isolated from 1-month-old, flash-frozen WT and Pkd1 RC/RC kidneys ( Figure  1C) , from left tibias of P25 WT and Pkd1 RC/del2 males (Supplemental Figure 4A , tibias were sonicated in 200 μl TRIzol before RNA isolation), or from cultured CD cells isolated from 1-month-old WT and Pkd1 RC/RC kidneys (Supplemental Figure 6) . RNA was isolated using the Qiagen RNeasy Kit, and RT was performed with the SuperScript III RT Kit (Invitrogen).
For Pkd1 cDNA analysis, exons 27-33 were amplified (762 bp or 669 bp, splice variant skipping exon 31; ref. 105) . RT analysis of osteocalcin, Runx2, and Gapdh was performed as previously described (71) . RT analysis of ER stressors was performed using primers to the murine mRNA (Hspa5, 335 bp; Herpud1, 301 bp; Xbp1, 205 bp; Actb: 397 bp). Fragments were quantified using ImageJ software.
Histological analysis. Animals were sacrificed by carbon dioxide exposure (Mayo IACUC guidelines) prior to organ harvest, and body/organ weights were recorded. Histology of 4% paraformaldehyde-fixed tissue was processed and H&E/Masson trichrome stained by the Mayo Department of Pathology. All tissues were examined by an experienced pathologist (S.H. Nasr). Kidneys (right), livers, pancreata, hearts, lungs, spleens, testes, and brains were analyzed from P25 and P180 Pkd1 RC/del2 animals and 12-month-old Pkd1 RC/RC animals. At all other time points, only kidneys were reviewed. At each time point, a minimum of 6 animals (3 per gender) were reviewed. Slides were observed using ×5 and ×10 objectives (Zeiss AxioObserver, Carl Zeiss). In cases in which the size of the histological section exceeded the visual field, single images were fused (AxioVision software).
US and KV measurements. US analysis of the right kidneys from WT (2 females, 2 males) and Pkd1 RC/RC mice (3 females, 3 males) at 3, 6, 9, and 12 months was performed as described previously (106) with the following modifications: 40-MHz scan head, 3D step size of 0.05 mm, and focal depth of 0.09 mm. KV calculations were performed by reconstructing a 3D image of kidney traces at a step size of 0.5 mm (VisualSonics software). A mean of 2 KV measurements was recorded. No cysts were found in Pkd1 RC/+ animals at 12 months.
BUN/cAMP measurements. Blood plasma was separated (6,000 g, 15 minutes at 4°C) from blood isolated by cardiac puncture and used for the BUN assay (BUN-Urea, BioAssay Systems), and cAMP levels (Direct cAMP EIA Kit, ENZO) were measured from 100 to 200 mg of flashfrozen kidney (left). Both assays were performed following the manufacturer's protocol.
Micro-CT analysis. Micro-CT was performed on the right femurs of 3 P25 WT and Pkd1 RC/del2 males using the μCT35 system (Scanco Medical) at the Mayo Bone Histomorphometry Core. The femur was oriented along the rotational axis of the scanner in a 70-kVP/180-mAs x-ray tube and scanned at an integration time of 300 ms. Sections were taken at an element size of 0.007 mm (trabecular bone, 233 sections; cortical bone, 50 sections). Cortical percentage of bone volume/tissue volume (%BV/TV) was determined by tracing the bone outline of all 50 sections. The %BV/TV values are the mean of duplicate measurements.
IF labeling. Tissues were prepared for IF labeling as previously described (10). Biotinylated-LTA, -DBA, and -PNA (1:250, Vector Laboratories); TH (1:200, Santa Cruz Biotechnology Inc.); and PCNA (1:100, Santa Cruz
